Pliant Therapeutics Secures FDA Fast Track Status For Liver Disease Drug
[ad_1] Pliant Therapeutics PLRX received Fast Track designation for its lead asset PLN-74809 from the U.S. Food and Drug Administration (FDA) for the potential treatment of primary sclerosing cholangitis (PSC).…